Cognition Therapeutics (CGTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CGTX Cognition Therapeutics

Watchlist

0.421
+0.011+2.63%

Close Sep 27 16:00 ET

0.420
-0.001-0.17%

Post 18:37 ET

16.89MMarket Cap-452P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
GlobeNewswireSep 3 07:30 ET
Express News | Cognition Therapeutics Shares Are Trading Higher After the Company Announced Results From Its SEQUEL Study of CT1812 for Alzheimer's Disease
BenzingaAug 22 09:21 ET
Cognition Therapeutics Reports Positive Results for Alzheimer's Drug in Study
MT NewswiresAug 22 08:25 ET
Express News | Cognition Therapeutics Publishes Eeg Findings From Phase 2 Sequel Study of Ct1812 in Mild-to-Moderate Alzheimer’s Disease
ReutersAug 22 07:31 ET
Cognition Therapeutics Publishes EEG Findings From Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease
GlobeNewswireAug 22 07:31 ET
Earnings Call: Cognition Therapeutics Reports Positive SHINE Trial Results
InvestingAug 12 10:08 ET

Comments

Stock Region

Aug 26 12:50

Therapeutics Company Publishes EEG Findings From Alzheimer's Treatment Study

$CGTX - Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease.
Alzheimer’s disease, a progressive neurodegenerative disorder, remains one of the most challenging areas of study in medical research. The pursuit of effective treatments has led to numerous studies and trials aimed at understanding and mitigating the effects of this disease. Recently, Cognit...

Trytosaveabit

Aug 22 06:33

Update

$Cognition Therapeutics (CGTX.US)$ Reuters· just
Cognition Therapeutics Publishes Eeg Findings From Phase 2 Sequel Study of Ct1812 in Mild-to-Moderate Alzheimer’s Disease

Jaguar8

Aug 22 06:32

NEWS

$Cognition Therapeutics (CGTX.US)$
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Cognition Therapeutics (NASDAQ: CGTX) has published results from the SEQUEL study of CT1812, their lead candidate for Alzheimer's disease treatment, in The Journal of Prevention of Alzheimer's Disease.
The single-site study measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer's after 29 days of treatment. CT1812-trea...

Rich365

Jul 31 14:30

$Cognition Therapeutics (CGTX.US)$ just came across this stock and wow what a deal.if ppl were smart they'd be jumping all over this.ive done a little bit of research on it.and from what I've read and seen this stock is way undervalued and should be trading between 1.50 -2.00 right now.according to market beat ,trade view, and motley fool this stock is set to double in the next 30 days and will be at the 7 to 10 dollar range by the end of this year.it has a steady cash flow as well.i thi...

Chew SW

Jul 30 07:39

Undervalued stock

$Cognition Therapeutics (CGTX.US)$ just a little not so good news, dropped by 50% since yesterday. almost hitting all time low. should rebound back to 1.50

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CGTX Cognition Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target